These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 2414311

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [The prognostic value of thyroid stimulating antibodies after antithyroid drug treatment of Graves' disease].
    Li J, Gao H, Xu L.
    Zhonghua Yi Xue Za Zhi; 1994 Apr; 74(4):218-20, 254-5. PubMed ID: 7922762
    [Abstract] [Full Text] [Related]

  • 25. Response to TRH, serum thyroid hormone concentration, and serum markers of autoimmunity after antithyroid therapy in Graves' disease.
    Lamberg BA, Aro A, Saarinen P, Tötterman T, Mäkinen T.
    J Endocrinol Invest; 1978 Jan; 1(1):9-16. PubMed ID: 90688
    [No Abstract] [Full Text] [Related]

  • 26. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
    Tamai H, Hayaki I, Kawai K, Komaki G, Matsubayashi S, Kuma K, Kumagai LF, Nagataki S.
    J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
    [Abstract] [Full Text] [Related]

  • 27. Thyrotropin (TSH)-releasing hormone stimulation test responses employing third and fourth generation TSH assays.
    Spencer CA, Schwarzbein D, Guttler RB, LoPresti JS, Nicoloff JT.
    J Clin Endocrinol Metab; 1993 Feb; 76(2):494-8. PubMed ID: 8432796
    [Abstract] [Full Text] [Related]

  • 28. Outcome of Graves' disease after antithyroid drug treatment in Taiwan.
    Wang PW, Liu RT, Tung SC, Chien WY, Lu YC, Chen CH, Kuo MC, Hsieh JR, Wang ST.
    J Formos Med Assoc; 1998 Sep; 97(9):619-25. PubMed ID: 9795530
    [Abstract] [Full Text] [Related]

  • 29. Predictor of outcome of hyperthyroidism due to Graves disease: serum triiodothyronine/thyroxine ratio.
    Khanna CM, Shankar LR, Jaggi CB, Bansal JK, Chugh P.
    J Assoc Physicians India; 1996 Feb; 44(2):98-101. PubMed ID: 10999059
    [Abstract] [Full Text] [Related]

  • 30. Changes in thyroid function in euthyroid subjects with a family history of Graves' disease: a follow-up study of 69 patients.
    Tamai H, Ohsako N, Takeno K, Fukino O, Takahashi H, Kuma K, Kumagai LF, Nagataki S.
    J Clin Endocrinol Metab; 1980 Nov; 51(5):1123-7. PubMed ID: 6774999
    [Abstract] [Full Text] [Related]

  • 31. Serum thyroglobulin changes in patients with Graves' disease treated with long term antithyroid drug therapy.
    Kawamura S, Kishino B, Tajima K, Mashita K, Tarui S.
    J Clin Endocrinol Metab; 1983 Mar; 56(3):507-12. PubMed ID: 6185525
    [Abstract] [Full Text] [Related]

  • 32. [Evaluation of effects of antithyroid drug treatment based mainly on the TRH test].
    Irie M, Enomoto K, Inoue K, Enomoto H, Nukii T.
    Horumon To Rinsho; 1974 Feb; 22(2):249-50. PubMed ID: 4136015
    [No Abstract] [Full Text] [Related]

  • 33. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ, Wiersinga WM, Prummel MF.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
    [Abstract] [Full Text] [Related]

  • 34. Clinical experience with sensitive thyrotropin measurements: diagnostic and therapeutic implications.
    Bayer MF, Kriss JP, McDougall IR.
    J Nucl Med; 1985 Nov; 26(11):1248-56. PubMed ID: 3840528
    [Abstract] [Full Text] [Related]

  • 35. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M, Nagasawa T.
    N Engl J Med; 1991 Apr 04; 324(14):947-53. PubMed ID: 1900575
    [Abstract] [Full Text] [Related]

  • 36. Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism?
    Lucas A, Salinas I, Rius F, Pizarro E, Granada ML, Foz M, Sanmartí A.
    J Clin Endocrinol Metab; 1997 Aug 04; 82(8):2410-3. PubMed ID: 9253309
    [Abstract] [Full Text] [Related]

  • 37. Sensitivity of thyroids to endogenous thyrotrophin in patients with Graves' disease.
    Tamai H, Nagai K, Uehata S, Komaki G, Kiyohara K, Miyauchi A, Kuma K, Kumagai LF, Nagataki S.
    Exp Clin Endocrinol; 1990 Dec 04; 96(3):279-87. PubMed ID: 2128053
    [Abstract] [Full Text] [Related]

  • 38. Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission.
    García-Mayor RV, Páramo C, Luna Cano R, Pérez Mendez LF, Galofré JC, Andrade A.
    J Endocrinol Invest; 1992 Dec 04; 15(11):815-20. PubMed ID: 1283984
    [Abstract] [Full Text] [Related]

  • 39. [Proceedings: T3 suppression test and TSH and prolactin reactions to TRH in patient with Basedow's disease under treatment with thyroid antagonists].
    Ikeda H, Imai Y, Uchimura H, Yamaji T, Matsuzaki S.
    Nihon Naibunpi Gakkai Zasshi; 1974 Feb 20; 50(2):108. PubMed ID: 4141667
    [No Abstract] [Full Text] [Related]

  • 40. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration.
    Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, Le Guerrier AM, Delambre C, Derennes V.
    J Clin Endocrinol Metab; 1990 Mar 20; 70(3):675-9. PubMed ID: 1689737
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.